B. Müller‐Oerlinghausen

Author

Also Known As

B MULLEROERLINGHAUSEN, B MÜLler-Oerlinghausen, B Müller-Oerlinghausen, B. Muller-Oerlinghausen, B. Müller-Oerlinghausen, B. MÜLLER-OERLINGHAUSEN, B. MÜller-Oerlinghausen, B. Müller-Oerlinghausen, B. Müller‐Oerlinghausen, B. Müller-Oerlinghausen

487

Publications

10.3K

Citations

H-Index

151

Concepts

All Affiliations

Freie Universität Berlin Charité - Universitätsmedizin Berlin German Medical Association Arzneimittelkommission der deutschen Ärzteschaft Humboldt-Universität zu Berlin

About

B. Müller‐Oerlinghausen is an author at Freie Universität Berlin specializing in medicine, psychiatry, and psychopathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	77	4K
2	Health Sciences	11	11	324
3	Law	1	1	25
4	Natural Sciences	1	1	19
5	Public Health	1	1	15

B. Müller‐Oerlinghausen

134

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry Pierre Baumann, Christoph Hiemke, S. Ulrich, Pharmacopsychiatry	2004	410
The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry I. Gaertner, Pierre Baumann, Christoph Hiemke, Pharmacopsychiatry Psychiatric EvaluationPsychotropic MedicationPsychopharmacologyPharmacotherapySocial Sciences	2005	343
Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study W. Greil, Wolfgang Ludwig‐Mayerhofer, N. Erazo, Journal of Affective Disorders PsychiatryPsychotropic MedicationLithium Versus CarbamazepineDepressionNeuropharmacology	1997	262
Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions Joerg Hasford, M. Goettler, K.-H. Munter, Journal of Clinical Epidemiology Drug SafetyDrug HypersensitivitySpontaneous Reporting SystemAdverse Drug ReactionsAdverse Event	2002	224
Effect of Prophylactic Treatment on Suicide Risk in Patients with Major Affective Disorders K. Thies-Flechtner, B. Müller‐Oerlinghausen, Wilda Seibert, Pharmacopsychiatry Psychological Co-morbiditiesRecent FindingsMental HealthPsychologySocial Sciences	1996	209
Differential Response to Lithium and Carbamazepine in the Prophylaxis of Bipolar Disorder W. Greil, Dipl-Stat Kleindienst Nikolaus, Dipl-Psych Erazo Natalia, Journal of Clinical Psychopharmacology	1998	209
Time experience and time judgment in major depression, mania and healthy subjects. A controlled study of 93 subjects Tom Bschor, Marcus Ising, Michael Bauer, Acta Psychiatrica Scandinavica	2004	207
The impact of the <i>CYP2D6</i> polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment Jürgen Brockmöller, Julia Kirchheiner, Jürgen Schmider, Clinical Pharmacology & Therapeutics	2002	202
The suicide prevention effect of lithium: more than 20 years of evidence—a narrative review Ute Lewitzka, Emanuel Severus, Rita Bauer, International Journal of Bipolar Disorders	2015	193
Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication B. Müller‐Oerlinghausen, B. Müser-Causemann, J. Volk Journal of Affective Disorders PsychiatryAddictionHigh-risk Patient GroupPsychotropic MedicationSuicide	1992	176

Page 1